De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Sirio Pharma Inkomsten in het verleden
Verleden criteriumcontroles 5/6
Sirio Pharma has been growing earnings at an average annual rate of 9%, while the Personal Products industry saw earnings growing at 9.9% annually. Revenues have been growing at an average rate of 18.8% per year. Sirio Pharma's return on equity is 11.9%, and it has net margins of 8.3%.
Belangrijke informatie
9.0%
Groei van de winst
5.9%
Groei van de winst per aandeel
| Personal Products Groei van de industrie | 7.8% |
| Inkomstengroei | 18.8% |
| Rendement op eigen vermogen | 11.9% |
| Nettomarge | 8.3% |
| Volgende winstupdate | 24 Oct 2024 |
Recente prestatie-updates uit het verleden
Recent updates
The Market Lifts Sirio Pharma Co., Ltd. (SZSE:300791) Shares 27% But It Can Do More
Sep 30
Is Sirio Pharma (SZSE:300791) Using Too Much Debt?
Sep 23Sirio Pharma Co., Ltd.'s (SZSE:300791) Prospects Need A Boost To Lift Shares
Aug 01Sirio Pharma (SZSE:300791) Will Be Hoping To Turn Its Returns On Capital Around
Jun 30Is Sirio Pharma (SZSE:300791) A Risky Investment?
Jun 12An Intrinsic Calculation For Sirio Pharma Co., Ltd. (SZSE:300791) Suggests It's 24% Undervalued
Apr 24Sirio Pharma (SZSE:300791) Seems To Use Debt Quite Sensibly
Mar 06Opbrengsten en kosten
Hoe Sirio Pharma geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 4,028 | 334 | 698 | 131 |
| 31 Mar 24 | 3,831 | 315 | 658 | 119 |
| 31 Dec 23 | 3,582 | 281 | 627 | 110 |
| 30 Sep 23 | 3,222 | 221 | 564 | 95 |
| 30 Jun 23 | 2,941 | 204 | 517 | 88 |
| 31 Mar 23 | 2,788 | 227 | 485 | 84 |
| 01 Jan 23 | 2,507 | 212 | 432 | 81 |
| 30 Sep 22 | 2,409 | 208 | 408 | 85 |
| 30 Jun 22 | 2,315 | 196 | 398 | 82 |
| 31 Mar 22 | 2,283 | 189 | 377 | 84 |
| 31 Dec 21 | 2,369 | 232 | 386 | 83 |
| 30 Sep 21 | 2,361 | 272 | 350 | 74 |
| 30 Jun 21 | 2,316 | 279 | 335 | 74 |
| 31 Mar 21 | 2,216 | 265 | 336 | 71 |
| 31 Dec 20 | 2,067 | 257 | 310 | 65 |
| 30 Sep 20 | 1,865 | 209 | 327 | 68 |
| 30 Jun 20 | 1,710 | 178 | 312 | 66 |
| 31 Mar 20 | 1,554 | 156 | 285 | 62 |
| 31 Dec 19 | 1,580 | 143 | 279 | 66 |
| 30 Sep 19 | 1,625 | 186 | 254 | 66 |
| 31 Dec 18 | 1,595 | 203 | 238 | 62 |
| 31 Dec 17 | 1,330 | 104 | 225 | 46 |
| 31 Dec 16 | 786 | 704 | 151 | 41 |
Kwaliteitswinsten: 300791 has high quality earnings.
Groeiende winstmarge: 300791's current net profit margins (8.3%) are higher than last year (6.9%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 300791's earnings have grown by 9% per year over the past 5 years.
Versnelling van de groei: 300791's earnings growth over the past year (64.2%) exceeds its 5-year average (9% per year).
Winst versus industrie: 300791 earnings growth over the past year (64.2%) exceeded the Personal Products industry -7.3%.
Rendement op eigen vermogen
Hoge ROE: 300791's Return on Equity (11.9%) is considered low.